Abstract

OBJECTIVES: This study aimed to investigate the association between first-trimester screening maternal serum markers (free human chorionic gonadotropin-beta (β-hCG), pregnancy-associated plasma protein-A, and adverse pregnancy outcomes (gestational hypertension, preeclampsia, preterm delivery, intrauterine growth restriction, oligohydramnios, intrauterine ex-fetus, abruptio placentae, and gestational diabetes mellitus). STUDY DESIGN: This was a retrospective cohort study including 1516 women who delivered a singleton pregnancy at GATA Haydarpasa Education Hospital from 2006 to 2009. Patients with multiple pregnancies, chromosome aberrations, or fetal anomalies were excluded. Extreme values of corrected- pregnancy-associated plasma protein-A and free β-hCG, and their association with adverse pregnancy outcomes were analyzed. RESULTS: Adverse pregnancy outcomes at the cutoff level of ≤0.25 c-pregnancy-associated plasma protein-A MOM values positive likelihood ratio (+LR) was 7.5 (95%CI 2.426-19.836) and had a significant correlation (r=0.108, p<0.01). It was also a significant correlation with adverse pregnancy outcomes (r=0.189, p<0.01) at the cut-off level of ≤0.50 corrected-pregnancy-associated plasma protein-A MOM values and the +LR was 2.388 (95%CI 1.889-2.991). Association between low corrected-pregnancy-associated plasma protein-A MOM values and adverse pregnancy outcomes were statistically significant and had a poor association (AUC, 0.630 95%CI 0.596-0.663, p<0.01). Preeclampsia was statistically significant, however had a fair association (AUC, 0.74 95% CI 0.690-0.802, p<0.01). Preterm birth was statistically significant but had a poor association (AUC, 0.568 95% CI 0.512-0.624, p<0.05). CONCLUSION: First-trimester maternal serum low pregnancy-associated plasma protein-A values are significantly associated with adverse pregnancy outcomes. It may be a useful tool to predictive not only chromosome anomalies but also adverse pregnancy outcomes.

Highlights

  • Association between low corrected-pregnancy-associated plasma protein-A Multiples of median values (MOM) values and adverse pregnancy outcomes were statistically significant and had a poor association (AUC, 0.630 95%CI 0.596-0.663, p

  • Evidence is lacking to support an association between free β-hCG and non-chromosomal adverse pregnancy outcomes [19,22,23]. In this retrospective cohort study, we aimed to investigate the relationship between the first-trimester screening maternal serum markers especially corrected pregnancy-associated plasma protein-A (PAPPA) levels, and adverse pregnancy outcomes such as gestational hypertension, preeclampsia, IUGR, oligohydramnios, preterm birth, intrauterine ex fetus (IUEF), gestational diabetes mellitus (GDM), placental abruption

  • This study aimed to investigate the relationship between the first-trimester screening maternal serum markers especially corrected PAPPA levels and adverse pregnancy outcomes such as gestational hypertension (GHT), preeclampsia, IUGR, oligohydramnios, preterm birth, IUEF, GDM, and abruptio placentae

Read more

Summary

Introduction

First-trimester screening tests were found to be effective for trisomy 21 screening [1,2,3,4,5] This screening technique is used to evaluate fetal nuchal translucency (NT) ultrasound and maternal serum markers pregnancy-associated plasma protein-A (PAPPA) and free human chorionic gonadotropin beta subunit (β-hCG) [6,7,8]. PAPPA is a secreted metalloprotease responsible for the cleavage of IGF binding protein-4 in the ovary [8,9]. Investigation of Association with First-Trimester Free Human Chorionic Gonadotropin - ß, Pregnancy - Associated Plasma Protein-A, and Adverse Pregnancy Outcomes Gynecol Obstet Reprod Med. 2021;Article in Press

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call